ClinicalTrials.gg
Active, not recruitingNCT07475507Updated Mar 16, 2026

Effect of PEEK and Titanium Framework Reinforcement on Marginal Bone Loss Around Implants Supporting a Fixed All-on-four Prosthesis in Completely Edentulous Mandibles

An interventional study of Titanium framework reinforced all on four prosthesis and PEEK framework reinforced all on four prosthesis in Prosthodontics, Implants, Dental and Prosthesis, sponsored by Cairo University. Active, not recruiting at 1 site in Egypt. Open to participants aged 45 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Aug 2024, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
45 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Alveolar Bone Loss by Cairo University — 10 open to participants now, 11 under way, none of them phase 3. Alveolar Bone Loss · Cairo University.

Enrollment
11th of 30
20 · median 20
Started
2024
with 5 others
No phase
29 of 30
10 open now
Primary completion
2026-12
later than 9 of 10 live
Registered
26th of 30
by date

Among the 30 studies in Alveolar Bone Loss by Cairo University, this one is the 11th largest by enrollment, is one of 6 that started in 2024, is one of 29 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 26th registered.

Alveolar Bone Loss

320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

Browse Alveolar Bone Loss studies →

Open to participants now

10 of the 30 studies in Alveolar Bone Loss by Cairo University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.

This study: 45 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Alveolar Bone Loss by Cairo University, or all of them as a file.
02

Study summary

A fixed all-on-four prosthesis will be constructed for the lower arch for each patient and the marginal bone loss will be evaluated at baseline, 3,6,9 and 12 months.

03

Conditions studied

  • Prosthodontics
  • Implants, Dental
  • Prosthesis
  • Bone Loss, Alveolar

Browse trials for

04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completely edentulous patients requesting a fixed, implant supported restoration.
  2. Patients aged from 45 to 60, able to sign an will be considered eligible for this trial.
  3. Implant sites must allow the placement of four implants.
  4. Non- heavy Smokers will be included (smoking up to 10 cigarettes/day)
  5. In case of post-extraction sites, they must have been healed for at least 3 months before being treated in the study.
  6. Patients with no systemic condition that may interfere with implant placement (e.g., or immunocompromised patients, patients under treatment of intravenous amino-bisphosphonates)

    -

Exclusion criteria

Exclusion Criteria:

  1. Patients with poor oral hygiene and motivation.
  2. Female patients taking any medical treatment for management of osteoporosis.
  3. Drug abusers.
  4. Psychiatric problems or unrealistic expectations.
  5. Patients with active infection or inflammation in the planned implant area at the time of implant placement.
  6. Immuno-compromised patients (Diabetic with > 7 or patients undergoing chemo or radiotherapy or bisphosphonates)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Other
    Titanium framework reinforced all on four prosthesis

    Active Comparator: Titanium reinforced fixed all-on-four prosthesis

    Other: Titanium framework reinforced all on four prosthesis

  • Other
    PEEK framework reinforced all on four prosthesis

    Other: PEEK framework reinforced all on four prosthesis

Interventions

  • OtherTitanium framework reinforced all on four prosthesis

    Titanium frameworks provided many advantages as their biocompatibility, corrosion resistance, relatively lower weight and high mechanical properties as well as avoiding the casting errors and technique sensitivity

  • OtherPEEK framework reinforced all on four prosthesis

    Fabricating a fixed prosthesis for patients with completely edentulous mandibles reinforced with PEEK

06

What researchers measure

Primary outcomes

  1. Marginal bone loss

    Marginal bone loss around each dental implant using parallel technique in digital periodical radiographs which will be measured in mm from the crestal bone level at the implant platform.

    Time frame: 12 months at intervals (0,3,6,9and 12 months)

Secondary outcomes

  1. Bone density

    Bone density around dental implants will be measured using digora digital radiographs which will be measured in hounsfield units.

    Time frame: 12 months at intervals (0,3,6,9and 12 months)

07

Study locations

1 site
08

References and documents

Publications

  • de Araujo Nobre M, Moura Guedes C, Almeida R, Silva A, Sereno N. Hybrid Polyetheretherketone (PEEK)-Acrylic Resin Prostheses and the All-on-4 Concept: A Full-Arch Implant-Supported Fixed Solution with 3 Years of Follow-Up. J Clin Med. 2020 Jul 10;9(7):2187. doi: 10.3390/jcm9072187. PubMed 32664393 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 169 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 28 months is above that.

Counting every sponsor, half of 169 studies reached it within 18 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Mar 16, 2026
StartActual
Aug 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475507
Lead sponsor
Cairo University
Responsible party
Ahmed Mohamed Hamed Khalaf (Assistant lecturer of Prosthodontics, Cairo University) — Principal investigator
First posted
Mar 16, 2026
Start date
Aug 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion